16 June 2016 - The Transparency Commission will consider the reimbursement of glatiramer acetate (Copaxone), ruxolitinib phosphate (Jakavi), clobazam (Likozam) and edoxaban tosylate (Lixiana).  The Commission will also review the anti-cholinesterase inhibitors for Alzheimer's disease and the biological agents (Benepali, Cosentyx, Humira, Simponi, Stelara & Enbrel).

For more details, go to: http://www.has-sante.fr/portail/upload/docs/application/pdf/2016-06/ordre_du_jour_ct_22062016.pdf